Recent Label Changes and FDA Safety Signals
- ETOPOPHOS: Warning for this chemothe...
- BAVENCIO: Myocarditis-Myositis-Myas...
- LOQTORZI: Warning of immune-related...
- BESREMI: Psychiatric reactions hav...
- BENLYSTA: Stevens-Johnson syndrome ...
- COTELLIC: New subsection with posta...
- FORTAMET: Risk of lactic acidosis i...
- JANUMET XR: Risk of lactic acidosis i...
- JENTADUETO: Risk of lactic acidosis i...
- KAZANO: Risk of lactic acidosis i...
Poll
Subscribe to our free consumer-friendly health newsletter:
Medical research, new treatments, drug safety, health tips and more; delivered every other Sunday.
2026 New and Expanded Drug Approvals:
August 2026 New and Expanded Drug Approvals: for Prostate Cancer, Plasma Transfusion, ADHD, OTC Pain, Melanoma, More
Check out our new FDA Adverse Event Summaries:
Check out our one-page
summary of AEMS reports covering older drugs like:
Amlodopine Besylate (Amlodopine is a commonly-used calcium channel
blocker drug used to treat high blood pressure) as well as newer drugs.
Run a search and click the link (if available) for the drug's "FDA
Adverse Event" summary of
Recent Reviews
9/15/2026
Top 10 Treatment
Categories
